General Updates

July 21, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 532531 Scrip Code: STAR Dear Madam/ Sir, Sub: Submission of Business Responsibility & Sustainability Report for FY26 Pursuant to Regulation 34(2)(f) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026. This is for your information and records. Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No.: A30515 Encl. As above Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India |Tel: +91 80 6784 0000 Regd. Off: ‘Cyber One’, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924/3199 corpcomm@strides.com; www.strides.com Business Responsibility & Sustainability Report Section A: General Disclosures Details of the listed entity: Question Response 1. Corporate Identity Number (CIN) of the Entity L24230MH1990PLC057062 2. Name of the Listed Entity Strides Pharma Science Limited (“Strides” / “Company”) 3. Year of Incorporation 1990 4. Registered Office Address ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India 5. Corporate Office Address Strides House, Bilekahalli, Bannerghatta Road, Bangalore – 560 076 6. E-mail investors@strides.com 7. Telephone +91 80 6784 0290 8. Website www.strides.com 9. Financial Year for which report is being done FY 2025-26 10. Name of the Stock Exchange(s) where shares The National Stock Exchange of India Limited (NSE) are listed BSE Limited (BSE) 11. Paid-up Capital (I) 92,17,27,140 12. Name and contact details (telephone, email) of the Ms. Sormistha Ghosh person who may be contacted in case of queries on Group General Counsel, Chief Risk & Sustainability Officer the BRSR report Ph: +91 80 6784 0290 Email: investors@strides.com 13. Reporting Boundary Financial disclosures – For Strides, on a standalone basis Other (Standalone or Consolidated basis) disclosures - For Strides and one of its Wholly owned Subsidiary based in India, i.e., Arco Lab Private Limited (“Arcolab”) 14. Name of assurance provider DNV Business Assurance India Private Limited 15. Type of assurance obtained Limited Products and Services: 16. Details of business activities (accounting for 90% of the turnover): Description of Main Activity Description of Business Activity %Turnover of the entity 1. Manufacturing Chemical and chemical products, 100% pharmaceuticals, medicinal chemical, and botanical products 17. Product/ Services sold by the entity (accounting for 90% of the entity’s turnover): Sl. %of total turnover Product/ Service NIC Code No. contributed 1. Manufacturing 21002 100% Operations: 18. Number of locations where plants and/or operations/ offices of the entity are situated: Location Number of Plants Number of Offices Total National 5 2 7 Bangalore, Karnataka: 2 facilities & 1 Registered office at Navi Mumbai, R&D Centre; Maharashtra; Puducherry: 1 facility; Corporate office at Bangalore, Karnataka Alathur, Tamil Nadu: 1 facility International* 3 8 11 USA- 1 facility US | UK | Singapore | South Africa | Italy | Canada | Switzerland | Kenya^ Italy- 1 facility Kenya- 1 facility^ 142 Strides Pharma Science Limited Corporate overview Statutory reports Financial statements *: Plants and offices are of step-down subsidiaries ^: Universal Corporation Limited was a subsidiary of Strides up to September 30, 2022. Effective September 30, 2022, it is an Associate Company of Strides. 19. Markets Served by the Entity: a. Number of Locations: Location Number National (No. of States) 0* International (No. of Countries) 106 *The Company doesn’t market products in India b. What is the contribution of exports as a percentage of the total turnover of the entity? 90.66%, on a standalone basis (“Total turnover” considered for the calculation includes other income) c. A brief on types of Customers S trides’ customers include wholesalers, large pharmacy chains, global donor-funded institutions, regional government bodies through MOH/Govt tender and large pharmaceutical companies. Employees: 20. Details as at the end of Financial Year 2025-26 a. Employees and Workers Employees (including differently abled) Male Female Particulars Total (A) Percentage Percentage No. Number (B) Number (B) (B/A) (B/A) 1. Permanent Employees 2,549 1,926 76% 623 24% 2. Other than Permanent 261 207 79% 54 21% Employees 3. Total Employees (1+2) 2,810 2,133 76% 677 24% Note: “Permanent Employee” includes all permanent employees on rolls of the Company and its Wholly owned Subsidiary in India, viz., Arcolab “Other than Permanent Employee” includes all individuals hired through third party vendors Workers (including differently abled) Male Female Particulars Total (A) Percentage Percentage No. Number (B) Number (B) (B/A) (B/A) 4. Permanent Workers 986 912 92% 74 8% 5. Other than Permanent 1,598 912 57% 686 43% Workers 6. Total Workers (4+5) 2,584 1,824 71% 760 29% Note: “Permanent Worker” includes all operators on the rolls of the Company and its wholly owned subsidiary in India, viz., Arcolab. “Other than Permanent Worker” includes those workers who are hired for contingent work and those who provide ancillary services; these workers are deployed in the company through third party vendors. b. Differently abled Employees and Workers Differently Abled Employees Male Female Particulars Total (A) Percentage No. Number (B) Number (B) Percentage (B/A) (B/A) 1. Permanent Employees 2,549 0 0.00% 0 0.00% 2. Other than Permanent 261 0 0.00% 0 0.00% Employees Annual Report 2025-26 143 3. Total Employees (1+2) 2,810 0 0.00% 0 0.00% Differently Abled Workers Male Female Particulars Total (A) Percentage No. Number (B) Number (B) Percentage (B/A) (B/A) 4. Permanent Workers 986 0 0.00% 0 0.00% 5. Other than Permanent 1,598 0 0.00% 0 0.00% Workers 6. Total Workers (4+5) 2,584 0 0.00% 0 0.00% 21. Participation/ Inclusion/ Representation of Women Total (A) Number of Female (B) Percentage (B/A) Board of Directors 8 2 25% Key Management Personnel (KMP) 5 1 20% 22. Turnover rate for permanent employees and workers: FY 2025 - 26 FY 2024 - 25 FY 2023 - 24 Male Female Total Male Female Total Male Female Total Permanent Employees 16 4.8 20.8 14.30% 4.40% 18.70% 15% 4% 19% Permanent Workers 1.9 0.1 2 1.40% 0.10% 1.50% 1% 0% 1% Note: Percentage calculated is on “Total Permanent Employees” and “Total Permanent Workers” for respective heads Holding, Subsidiary and Associate Companies (including joint ventures): 23. Names of holding/ subsidiary/ associate companies/ joint ventures Does the entity participate in Is it a holding/ Sl. Name of the holding/ subsidiary/ % of shares held by the Business Responsibility Subsidiary/ Associate/ No. associate company/ joint venture listed entity initiatives of the listed entity? Joint Venture (Yes/No) The details of the holding/ subsidiary/ associate/ joint venture companies are provided in Form No AOC-1, which is an annexure to the Board’s Report. Refer page 85 to 88 of the annual report. 24. CSR Details: (i) Whether CSR is applicable as per Section 135 of Applicable for Strides. Details of CSR activities undertaken are Companies Act, 2013 provided as an Annexure to the Board’s Report. Refer page 93 to 96 of the annual report. (ii) T urnover (in I Million) 21,801.36 (on a standalone basis) (iii) Net Worth (in I Million) 28,953.13 (on a standalone basis) Transparency and Disclosures Compliances: 25. Complaints/ Grievances on any of the principles (1-9) under the National Guidelines on Responsible Business Conduct: Financial Year 2025 - 26 Financial Year 2024 – 25 Grievance Number of Number of Stakehold [Showing first 8,000 characters — download PDF for full document]